Mineralocorticoid receptor antagonists: Their use and differentiation in Japan

Hypertension Research

Volumn 36, Issue 3, 2013, Pages 185-190

  Sato, Atsuhisa ^a  

^a International University of Health and Welfare Mita Hospital   (Japan)

Author keywords

aldosterone; chronic kidney disease; eplerenone; mineralocorticoid receptor antagonists; spironolactone

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; NELFINAVIR; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; RITONAVIR; SPIRONOLACTONE;

ACUTE KIDNEY FAILURE; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG USE; EDEMA; ESSENTIAL HYPERTENSION; GYNECOMASTIA; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; IC 50; IMPOTENCE; JAPAN; LIVER FAILURE; MASTALGIA; MENSTRUAL IRREGULARITY; MONOTHERAPY; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PROTEINURIA; REVIEW; SYSTOLIC BLOOD PRESSURE;

COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; JAPAN; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84874595479     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2012.182     Document Type: Review

References (52)

1. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H, on behalf of The Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Committee for Guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32: 1-107.
2. Saruta T, Kageyama S, Ogihara T, Hiwada K, Ogawa M, Tawara K, Gatlin M, Garthwaite S, Bittman R, Patrick J. Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study. J Clin Hypertens 2004; 6: 175-185.
3. Sato A, Fukuda S. Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. J Hum Hypertens 2010; 24: 387-394.
4. Jansen PM, Jan Danser AH, Imholz BP, van den Meiracker AH. Aldosterone-receptor antagonism in hypertension. J Hypertens 2009; 27: 680-691.
5. Krozowski ZS, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA 1983; 80: 6056-6060.
6. Funder JW, Krozowski Z, Myles K, Sato A, Sheppard KE, Young M. Mineralocorticoid receptors, salt, and hypertension. Recent Prog Hormone Res 1997; 52: 247-262.
7. Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol 2004; 217: 27-31.
8. Greenblatt DJ, Koch-Weser J. Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. JAMA 1973; 225: 40-43.
9. Hu X, Li S, McMahon EG, Lala DS, Rudolph AE. Molecular mechanism of mineralocorticoid receptor antagonism by eplerenone. Mini-Rev Med Chem 2005; 5: 709-718.
10. Funder JW. The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure. Expert Opin Investig Drugs 2003; 12: 1963-1969.
11. Overdiek HWPM, Hermens WAJJ, Merkus FWHM. New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther 1985; 38: 469-474.
12. McInnes GT, Asbury MJ, Shelton JR, Harrison IR, Ramsay LE, Venning GR, Clarke JM. Activity of sulfur-containing intermediate metabolites of spironolactone. Clin Pharmacol Ther 1980; 27: 363-369.
13. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005; 10: 23-29.
14. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008; 31: 153-158.
15. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA. Longterm cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-918.
16. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295: 2638-2645.
17. Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S, Boscaro M. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 2007; 25: 177-186.
18. Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, Anagnostis P, Arthyros V, Mikhailidis DP. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 2008; 9: 509-515.
19. Parthasarathy HK, Menard J, White WB, Young Jr WF, Williams GH, Williams B, Ruilope LM, McInnes GT, Connell JM, MacDonald TM. A double-blind, randomized study comparing the antihypertensive effects of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011; 29: 980-990.
20. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29: 13-21.
21. Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003; 16: 781-788.
22. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68.
23. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-49.
24. Sato A, Saruta T, Funder JW. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 2006; 29: 211-216.
25. Pitt B, Zannad F, Remme W, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
26. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
27. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
28. Mihailidou AS, Le TYL, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009; 54: 1306-1312.
29. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-Left Ventricular Hypertrophy Study. Circulation 2003; 108: 1831-1838.
30. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy. Diabetes Care 2005; 28: 2106-2112.
31. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH. Beneficial impact of spironolactone on nephritic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542.
32. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51.
33. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind placebocontrolled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-262.
34. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951.
35. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003; 41: 1148-1155.
36. Weinberger M, White WB, Ruilope LM, MacDonald TM, Davidson RC, Roniker B, Patrick JL, Krause SL. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005; 150: 426-433.
37. Gross E, Rothstein M, Dombek S, Juknis HI. Effect of spironolactone on blood pressure and renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 2005; 46: 94-101.
38. Ando K, Ohtsu H, Arakawa Y, Kubota K, Yamaguchi T, Nagase M, Yamada A, Fujita T, on behalf of the EVALUATE Study Investigators. Rational and design of the Eplerenone combination versus conventional agents to lower blood pressure on urinary antialbuminuric treatment effect (EVALUATE) trial: a double-blinded randomized placebocontrolled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertens Res 2010; 33: 616-621.
39. Sundsfjord JA, Odegaard AE. Renin levels and spironolactone treatment in general practices: similar blood pressure lowering effect of spironolactone in low and normal renin patients. Eur J Clin Invest 1977; 7: 389-392.
40. Ogilvie RI, Piafsky KM, Ruedy J. Antihypertensive responses to spironolactone in normal renin hypertension. Clin Pharmacol Ther 1978; 24: 525-530.
41. Skluth HA, Gums JG. Spironolactone: a re-examination. Ann Pharmacol 1990; 24: 52-59.
42. Wolf RI, Mendlowitz M, Roboz J, Styan GPH, Kornfeld P, Weigl A. Treatment of hypertension with spironolactone. Double-blind study. JAMA 1966; 198: 121-127.
43. Jeunemaitre X, Chatellier G, Kraft-Jais C, Charru A, Devries C, Plouin PF, Corvol P, Menard J. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820-825.
44. Jeunemaitre X, Kreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin PF, Menard J, Corvol P. Long-term experience of spironolactone in essential hypertension. Kidney Int 1988; 34: S14-S17.
45. Huffman DH, Kampmann JP, Hignite CE, Azarnoff DL. Gynecomastia induced in normal males by spironolactone. Clin Pharmacol Ther 1978; 24: 465-473.
46. Schersten B, Thulin T, Kuylenstierna J, Engstrom M, Karlberg BE, Tolagen K, Nordlander S, Nilsson G. Clinical and biochemical effects of spironolactone administered once daily in primary hypertension. Multicenter Sweden Study. Hypertension 1980; 2: 672-679.
47. Spark RF, Melby JC. Aldosteronism in hypertension: the spironolactone response test. Ann Intern Med 1968; 69: 685-691.
48. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925-930.
49. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002; 15: 333-339.
50. Lane DA, Shah S, Beevers G. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007; 25: 891-894.
51. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR. on behalf of the Anglo-Scandinavian Cardiac Outcome Trial Investigation. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839-845.
52. Levy DG, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004; 89: 2736-2740.